These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36596568)

  • 1. The cost-effectiveness of universal hepatitis B screening for reaching WHO diagnosis targets in Australia by 2030.
    Xiao Y; Hellard ME; Thompson AJ; Seaman C; Howell J; Scott N
    Med J Aust; 2023 Mar; 218(4):168-173. PubMed ID: 36596568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation.
    Su S; Wong WC; Zou Z; Cheng DD; Ong JJ; Chan P; Ji F; Yuen MF; Zhuang G; Seto WK; Zhang L
    Lancet Glob Health; 2022 Feb; 10(2):e278-e287. PubMed ID: 35063115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis.
    Nayagam S; Conteh L; Sicuri E; Shimakawa Y; Suso P; Tamba S; Njie R; Njai H; Lemoine M; Hallett TB; Thursz M
    Lancet Glob Health; 2016 Aug; 4(8):e568-78. PubMed ID: 27443782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening.
    Robotin MC; Kansil M; Howard K; George J; Tipper S; Dore GJ; Levy M; Penman AG
    J Hepatol; 2009 May; 50(5):990-8. PubMed ID: 19303657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of active-passive prophylaxis and antiviral prophylaxis during pregnancy to prevent perinatal hepatitis B virus infection.
    Fan L; Owusu-Edusei K; Schillie SF; Murphy TV
    Hepatology; 2016 May; 63(5):1471-80. PubMed ID: 26509655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact and Cost-Effectiveness of Biomedical Interventions on Adult Hepatitis B Elimination in China: A Mathematical Modelling Study.
    Wang X; Du Z; Wang Y; Wang J; Huang S; Wang Y; Gu J; Deng W; Gilmour S; Li J; Hao Y
    J Epidemiol Glob Health; 2023 Sep; 13(3):517-527. PubMed ID: 37349664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of screening immigrants for hepatitis B.
    Wong WW; Woo G; Jenny Heathcote E; Krahn M
    Liver Int; 2011 Sep; 31(8):1179-90. PubMed ID: 21745300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B.
    Hutton DW; Tan D; So SK; Brandeau ML
    Ann Intern Med; 2007 Oct; 147(7):460-9. PubMed ID: 17909207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland.
    Blach S; Schaetti C; Bruggmann P; Negro F; Razavi H
    Swiss Med Wkly; 2019 Mar; 149():w20026. PubMed ID: 30905063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness and budget impact analysis of facility-based screening and treatment of hepatitis C in Punjab state of India.
    Chugh Y; Premkumar M; Grover GS; Dhiman RK; Teerawattananon Y; Prinja S
    BMJ Open; 2021 Feb; 11(2):e042280. PubMed ID: 33589457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective.
    Veldhuijzen IK; Toy M; Hahné SJ; De Wit GA; Schalm SW; de Man RA; Richardus JH
    Gastroenterology; 2010 Feb; 138(2):522-30. PubMed ID: 19879275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India.
    Chugh Y; Dhiman RK; Premkumar M; Prinja S; Singh Grover G; Bahuguna P
    PLoS One; 2019; 14(8):e0221769. PubMed ID: 31465503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic Analysis and Budget Impact of Tenofovir and Entecavir in the First-Line Treatment of Hepatitis B Virus in Italy.
    Ruggeri M; Basile M; Coretti S; Drago C; Cicchetti A
    Appl Health Econ Health Policy; 2017 Aug; 15(4):479-490. PubMed ID: 28197805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016-30.
    Tordrup D; Hutin Y; Stenberg K; Lauer JA; Hutton DW; Toy M; Scott N; Bulterys M; Ball A; Hirnschall G
    Lancet Glob Health; 2019 Sep; 7(9):e1180-e1188. PubMed ID: 31353061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Universal Hepatitis B Antibody Screening and Vaccination in Pregnancy: A Cost-Effectiveness Analysis.
    Prabhu M; Susich MK; Packer CH; Hersch AR; Riley LE; Caughey AB
    Obstet Gynecol; 2022 Mar; 139(3):357-367. PubMed ID: 35115449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cost-effectiveness of community-based treatment of chronic hepatitis B in China].
    Zhang SX; Yang PC; Cai YL; Lin Y; Zou YH
    Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Jul; 38(7):860-867. PubMed ID: 28738456
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluating the cost-effectiveness of universal hepatitis B virus vaccination in Iran: a Markov model analysis.
    Mokhtari AM; Barouni M; Moghadami M; Hassanzadeh J; Dewey RS; Mirahmadizadeh A
    Hum Vaccin Immunother; 2021 Jun; 17(6):1825-1833. PubMed ID: 33734949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States.
    Guzauskas GF; Garbett S; Zhou Z; Spencer SJ; Smith HS; Hao J; Hassen D; Snyder SR; Graves JA; Peterson JF; Williams MS; Veenstra DL
    JAMA Netw Open; 2020 Oct; 3(10):e2022874. PubMed ID: 33119106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness Analysis of Antiviral Therapy for Untreated Minimally Active Chronic Hepatitis B to Prevent Liver Disease Progression.
    Lee H; Kim BK; Jang S; Ahn SH
    Clin Transl Gastroenterol; 2021 Feb; 12(2):e00299. PubMed ID: 33600103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.